The prevalence of silent acromegaly in prolactinomas is very low



The aim of this study was to evaluate the somatotroph axis in a large series of patients with prolactinoma to verify the prevalence of silent acromegaly in this population.


A hundred and forty-four patients were enrolled in a multicenter study: 90 were already on cabergoline (CAB) and enrolled in a cross-sectional arm (group A) with random PRL, GH and IGF-I determination on treatment (≥ 3 months), whereas 54 untreated patients were enrolled at diagnosis in a prospective arm (group B) with PRL, GH and IGF-I measurement before and after 6 and 12 months of treatment. In the presence of high IGF-I, CAB was withdrawn for 3 months and GH, IGF-I, PRL and GH during an oral Glucose Tolerance Test (OGTT) were obtained.


High IGF-I levels (ULN 1.01–1.56) were observed in 9 patients (6.25%, 5F). After CAB withdrawal, IGF-I levels normalized in 5/9 patients, GH was < 0.4 ng/ml after OGTT in 7/9 cases or at random GH determination in one case. After CAB re-introduction, IGF-I levels re-increased in a single case. Overall, a single young female patient harboring a macroadenoma in group A was diagnosed with silent acromegaly and underwent successful transsphenoidal removal of a GH/PRL-secreting adenoma.


The prevalence of silent acromegaly in prolactinomas (0.7%) is lower than previously reported and OGTT is helpful to recognize silent acromegaly. We suggest that the somatotroph axis should be evaluated at diagnosis in all cases and not systematically during follow-up.

This is a preview of subscription content, log in to check access.


  1. 1.

    Mulchahey JJ, Jaffe RB (1988) Detection of a potential progenitor cell in the human fetal pituitary that secretes both growth hormone and prolactin. J Clin Endocrinol Metab 66(1):24–32

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Lloyd RV, Anagnostou D, Cano M, Barkan AL, Chandler WF (1988) Analysis of mammosomatotropic cells in normal and neoplastic human pituitary tissues by the reverse hemolytic plaque assay and immunocytochemistry. J Clin Endocrinol Metab 66(6):1103–1310

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Bassetti M, Spada A, Arosio M, Vallar L, Brina M, Giannattasio G (1986) Morphological studies on mixed growth hormone (GH)- and prolactin (PRL)-secreting human pituitary adenomas coexistence of GH and PRL in the same secretory granule. J Clin Endocrinol Metab 62(6):1093–1100

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Wang M, Mou C, Jiang M, Han L, Fan S, Huan C, Qu X, Han T, Qu Y, Xu G (2012) The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol 166(5):797–802.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Rosário PW, Purisch S (2010) Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists. Arq Bras Endocrinol Metabol 54(6):546–549

    Article  PubMed  Google Scholar 

  6. 6.

    Bácsy E, Fazekas I, Slowik F, Pásztor E, Czirják S (1997) Transformation of a human mixed GH-PRL adenoma cell population in response to long-term bromocriptine treatment. Folia Histochem Cytobiol 35(2):69–74

    PubMed  Google Scholar 

  7. 7.

    Page MD, Bridges LR, Barth JH, McNichol AM, Belchetz PE (1996) Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. J Clin Endocrinol Metab 81(12):4484–4487

    CAS  PubMed  Google Scholar 

  8. 8.

    Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C (2003) Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 149(1):17–22

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575–596.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96(2):273–288.

    CAS  Article  Google Scholar 

  11. 11.

    Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265–273

    Article  Google Scholar 

  12. 12.

    Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH, Endocrine Society (2014) Acromegaly: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 99(11):3933–3951.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine Society (2011) Pituitary incidentaloma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:894–904

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Peacey SR, Shalet SM (2001) Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Ann Clin Biochem 38(Pt 4):297–303

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Manuylova E, Calvi LM, Hastings C, Vates GE, Johnson MD, Cave WT, Shafiq I (2016) Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Rep, pii: 16–0069.

  16. 16.

    Akirov A, Greenman Y, Glaser B, Schigol I, Mansiterski Y, Eizenberg Y, Shraga-Slutzky I, Shimon I (2018) IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary 21(4):406–413.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, Arnoux A, Young J, Souberbielle JC, Chanson P (2017) Classification of patients with GH disorders may vary according to the IGF-I assay. J Clin Endocrinol Metab 102(8):2844–2852

    Article  PubMed  Google Scholar 

  18. 18.

    Lopes MB (2010) Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 29(4):E2.

    Article  PubMed  Google Scholar 

  19. 19.

    Müller EE, Locatelli V, Cocchi D (1999) Neuroendocrine control of growth hormone secretion. Physiol Rev 79(2):511–607

    Article  PubMed  Google Scholar 

  20. 20.

    Tannenbaum GS, Ling N (1984) The Interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 115(5):1952–1957

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Arihara Z, Sakurai K, Yamashita R, Niitsuma S, Ueno T, Yamamura N, Yamada S, Inoshita N, Takahashi K (2014) Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. Tohoku J Exp Med 234(2):129–135

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO (1987) Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. J Clin Endocrinol Metab 64(6):1136–1141

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, Weiss MH (1981) Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47(4):761–771

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Osamura RY, Grossman A, Korbonits M, Kovacs K, Lopes MBS, Matsuno A, Trouillas J (2017) Pituitary adenoma. In WHO Classification of tumours of endocrine organs; Chapter 1: Tumors of the pituitary gland; WHO: Lyon, France, pp. 14–18.

  25. 25.

    Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify the pituitary neuroendocrine tumors (Pit-NET)s in 2020. Cancers (Basel), 12(2).

  26. 26.

    Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A (2010) Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 95(1):13–17

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Klibanski A, Zervas NT, Kovacs K, Ridgway EC (1987) Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J Neurosurg 66(6):806–811

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G (2017) Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 176(2):195–201

    CAS  Article  Google Scholar 

Download references


This research received grant from Ipsen Biopharmaceuticals (Protocol n. 359/2013).

Author information



Corresponding author

Correspondence to C. Bona.

Ethics declarations

Conflict of interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients filled informed consent statement for this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bona, C., Prencipe, N., Jaffrain-Rea, M.L. et al. The prevalence of silent acromegaly in prolactinomas is very low. J Endocrinol Invest (2020).

Download citation


  • Silent acromegaly
  • Prolactinoma
  • Dopamine agonists
  • Cabergoline